Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Schizophrenia Research

• Publication date

  2001-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0920-9964(00)00189-4PMID 11595399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia.

  2000cited by this paper
• Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

  1999cited by this paper
• Ceramide and sphingomyelinases in the regulation of stress responses.

  1999cited by this paper
• The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

  1998cited by this paper
• Alterations in erythrocyte aggregability in diabetics: The influence of plasmatic fibrinogen and phospholipids of the red blood cell membrane

  1998cited by this paper
• Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene

  1997cited by this paper
• Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

  1997cited by this paper
• Genetic variant near cytosolic phospholipase A2 associated with schizophrenia.

  1996cited by this paper
• Schizophrenia as a membrane lipid disorder which is expressed throughout the body.

  1996cited by this paper
• MRI volumetric measures and 31P MRS in schizophrenia

  1995cited by this paper
• Increased platelet phospholipase A2 activity in schizophrenia.

  1995cited by this paper
• An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy.

  1995cited by this paper
• A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases.

  1994cited by this paper
• DSM-IV: Diagnostic and Statistical Manual of Mental Disorders

  1994cited by this paper
• The sphingomyelin cycle and the second messenger function of ceramide.

  1994cited by this paper
• Red cell membrane fatty acids in schizophrenic patients with mainly positive or mainly negative symptoms

  1993cited by this paper
• Elevated PLA2 activity in schizophrenics and other psychiatric patients.

  1993cited by this paper
• Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients.

  1993cited by this paper
• 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia.

  1993cited by this paper
• New insights on mammalian phospholipase A2(s); comparison of arachidonoyl‐selective and ‐nonselective enzymes

  1993cited by this paper
• Erythrocyte membrane phospholipids in psychotic patients.

  1993cited by this paper
• A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP.

  1991cited by this paper
• Increased serum phospholipase A2 activity in schizophrenia: a replication study.

  1990cited by this paper
• Compensatory mechanisms in erythrocyte lipids in patients with atherosclerosis

  1988cited by this paper
• Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Membrane abnormalities in schizophrenia

  1982cited by this paper
• Red cell phospholipids in schizophrenia.

  1982cited by this paper
• Modified Jungnickel's reagent for detecting phospholipids and other phosphorus compounds on thin-layer chromatograms.

  1975cited by this paper
• The Distribution of the Phospholipid Fractions in the Red Cell Membrane of Schizophrenics

  1972cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper

• Serum lipid metabolic characteristics and potential biomarkers in first-episode schizophrenia

  2025cites this paper
• Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol.

  2024cites this paper
• Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotypes of schizophrenia

  2024cites this paper
• Case Report of Gardner-Diamond Syndrome

  2023cites this paper
• Nutritional roles and therapeutic potentials of dietary sphingomyelin in brain diseases

  2023cites this paper
• Comparative assessment of erythrocyte sphingolipid levels as potential cardiovascular health markers in women from Libya and Serbia: a small-scale study

  2023cites this paper
• Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target

  2022cites this paper
• Changes in the blood plasma lipidome associated with response to atypical antipsychotic treatments in schizophrenia

  2020cites this paper
• Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people.

  2020cites this paper
• Characterising phospholipids and free fatty acids in patients with schizophrenia: A case-control study

  2020cites this paper
• Evidence for Altered Metabolism of Sphingosine-1-Phosphate in the Corpus Callosum of Patients with Schizophrenia

  2020cites this paper
• Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients.

  2020cites this paper
• Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia.

  2019cites this paper
• Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders

  2017cites this paper
• Lipidomics, Biomarkers, and Schizophrenia: A Current Perspective.

  2017cites this paper
• Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations

  2016cites this paper
• Regulation of sphingomyelin metabolism

  2016cites this paper
• Genome Wide Analysis Identifies Sphingolipid Metabolism As A New Target Of Valproic Acid

  2016cites this paper
• The role of omega-3 fatty acids in the treatment of schizophrenia through modification of membrane phospholipids

  2016cites this paper
• Erythrocyte Aggregability Enables the Distinction between Negative and Depressive Symptoms among Schizophrenia and Schizoaffective Disorder Patients

  2014cites this paper
• Differences in the Lipid Domain Organization of Erythrocyte Membranes in Patients with Schizophrenia

  2014cites this paper
• Sphingolipids in psychiatric disorders and pain syndromes.

  2013cites this paper
• Comparative analysis of phospholipid composition in blood erythrocytes of various species of mouse-like rodents

  2011cites this paper
• Schizophrenia Spectrum Disorders and Risk for Cancer Morbidity and Mortality

  2011cites this paper
• Genetic association between schizophrenia and type-2 diabetes

  2011cites this paper
• Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy

  2009cites this paper
• Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics

  2009cites this paper
• Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia.

  2009cites this paper
• Phospholipid membrane abnormalities and reduced niacin skin flush response in schizophrenia.

  2008cites this paper
• High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides.

  2008cites this paper
• BanI polymorphism of cytosolic phospholipase A2 gene is associated with age at onset in male patients with schizophrenia and schizoaffective disorder.

  2008cites this paper
• Differential gene expression during terminal erythroid differentiation.

  2007cites this paper
• The PLA2G4A gene and negative symptoms in a Chinese population.

  2006cites this paper
• Membrane phospholipids and cytokine interaction in schizophrenia.

  2004cites this paper
• Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced.

  2004cites this paper
• Phospholipid and eicosanoid signaling disturbances in schizophrenia.

  2003cites this paper
• From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?

  2003cites this paper
• Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia.

  2003cites this paper
• Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview.

  2003cites this paper
• Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia.

  2003cites this paper
• Changes during hibernation in different phospholipid and free and esterified cholesterol serum levels in black bears.

  2002cites this paper
• The Role of Omega-3 Fatty Acids in the Treatment of Schizophrenia through Modification of Membrane Phospholipids

  year unknowncites this paper